XML 63 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Year Ended December 31,
201920182017
Pfizer Inc.40 %47 %47 %
Kite Pharma, Inc.34 %30 %—  
Sanofi Genzyme22 %16 %34 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):
As of December 31,
201920182017
Cash and cash equivalents$80,428  $140,418  $49,826  
Non-current restricted cash1,500  3,500  3,500  
Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows$81,928  $143,918  $53,326  
Restrictions on Cash and Cash Equivalents
A reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):
As of December 31,
201920182017
Cash and cash equivalents$80,428  $140,418  $49,826  
Non-current restricted cash1,500  3,500  3,500  
Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows$81,928  $143,918  $53,326  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
The impact of the adoption of ASC Topic 842 on the accompanying Consolidated Balance Sheet as of January 1, 2019 was as follows (in thousands):
December 31, 2018Adjustments Due to the Adoption of ASC Topic 842January 1, 2019
Assets:
Property and equipment, net$78,723  $(62,500) $16,223  
Operating lease right-of-use assets—  8,753  8,753  
Prepaid rent—  36,025  36,025  
Liabilities:
Operating lease liabilities - current(1)
—  1,408  1,408  
Deferred rent(1)
271  (271) —  
Build-to-suit lease obligation(2)
27,689  (27,689) —  
Operating lease liabilities - long-term(2)
—  7,933  7,933  
Accumulated deficit(562,696) 897  (561,799) 
___________________
(1) Operating lease liabilities – current and deferred rent are included in accounts payable and accrued liabilities on the Consolidated Balance Sheets.
(2) Build-to-suit lease obligation and operating lease liabilities – long-term are included in long-term portion of lease liabilities on the Consolidated Balance Sheets.